D. Boral Capital Reiterates Buy Rating for Beyond Air (NASDAQ:XAIR)

Beyond Air (NASDAQ:XAIR)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $10.00 price objective on the stock.

Other analysts have also issued research reports about the company. Rodman & Renshaw started coverage on Beyond Air in a research note on Tuesday, January 20th. They issued a “buy” rating for the company. Weiss Ratings reissued a “sell (e)” rating on shares of Beyond Air in a research note on Monday, December 22nd. Finally, Wall Street Zen raised shares of Beyond Air to a “sell” rating in a research note on Saturday, March 7th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $10.00.

Beyond Air Trading Down 3.3%

NASDAQ XAIR opened at $0.78 on Wednesday. The company has a quick ratio of 4.77, a current ratio of 5.12 and a debt-to-equity ratio of 2.65. The stock’s 50-day simple moving average is $1.15 and its two-hundred day simple moving average is $1.54. Beyond Air has a twelve month low of $0.67 and a twelve month high of $6.39. The company has a market capitalization of $8.21 million, a price-to-earnings ratio of -0.14 and a beta of 0.41.

Beyond Air (NASDAQ:XAIR) last posted its quarterly earnings data on Friday, February 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.31). The firm had revenue of $2.19 million during the quarter, compared to analysts’ expectations of $2.15 million. Beyond Air had a negative return on equity of 268.82% and a negative net margin of 447.75%. Research analysts forecast that Beyond Air will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of XAIR. Geode Capital Management LLC lifted its holdings in Beyond Air by 57.5% in the 4th quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock worth $49,000 after buying an additional 24,695 shares during the period. Alpine Global Management LLC purchased a new stake in Beyond Air in the third quarter worth $25,000. Alyeska Investment Group L.P. purchased a new stake in Beyond Air in the third quarter worth $1,753,000. Virtu Financial LLC bought a new stake in Beyond Air in the third quarter valued at $48,000. Finally, Osaic Holdings Inc. increased its position in Beyond Air by 26.4% during the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock valued at $29,000 after purchasing an additional 34,000 shares during the period. Hedge funds and other institutional investors own 31.50% of the company’s stock.

Beyond Air Company Profile

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.